Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
CYP2C19*2
Description:
CYP2C19*2 is a common loss-of-function variant of the CYP2C19 gene, studied in pharmacogenetics for its effects on drug metabolism.
Primary topic:
Pharmacogenetics and Drug Metabolism (54%)
Related topics:
Pharmacogenetics and Drug Metabolism (54%),
Antiplatelet Therapy and Cardiovascular Diseases (37%)
OpenAlex ID:
keywords/cyp2c19-2
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
2009
·
Alan R. Shuldiner
, Jeffrey R O'Connell
, et al.
·
JAMA
·
1,510
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
2006
·
J.-S. Hulot
, Alessandra Bura
, et al.
·
Blood
·
925
PDF
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
2007
·
J.T. BRANDT
, S.L. CLOSE
, et al.
·
Journal of Thrombosis and Haemostasis
·
731
Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease
2011
·
Jessica L. Mega
, Willibald Hochholzer
, et al.
·
JAMA
·
384
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
2002
·
M Scordo
, Vittorio Pengo
, et al.
·
Clinical Pharmacology & Therapeutics
·
346
PM Frequencies of Major CYPs in Asians and Caucasians
2003
·
Takaharu Mizutani
·
Drug Metabolism Reviews
·
238
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population
2003
·
Elena A. Gaikovitch
, Ingolf Cascorbi
, et al.
·
European Journal of Clinical Pharmacology
·
234
Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population
2004
·
M SCORDO
, Achille P Caputi
, et al.
·
Pharmacological Research
·
230
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
2007
·
Betti Giusti
, Anna Maria Gori
, et al.
·
Pharmacogenetics and Genomics
·
228
Genetic Polymorphism of Cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese Population
1998
·
Miyuki Kimura
, Ichiro Ieiri
, et al.
·
Therapeutic Drug Monitoring
·
205
General and Applied Toxicology
1994
·
S M Barlow
·
Occupational and Environmental Medicine
·
203
PDF
A New Genetic Defect in Human CYP2C19: Mutation of the Initiation Codon Is Responsible for Poor Metabolism of S-Mephenytoin
1998
·
Ronald J. Ferguson
, Sonia M.F. De Morais
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
200
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
2011
·
D. Sibbing
, W. Koch
, et al.
·
European Heart Journal
·
184
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel
2011
·
Michel Zabalza
, Isaac Subirana
, et al.
·
Heart
·
178
Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations
2015
·
I Fricke-Galindo
, C Céspedes-Garro
, et al.
·
The Pharmacogenomics Journal
·
177
Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
2002
·
Julia Kirchheiner
, Steffen Bauer
, et al.
·
Pharmacogenetics
·
170
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events
2010
·
Klaus A. Tiroch
, Dirk Sibbing
, et al.
·
American Heart Journal
·
164
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study
2010
·
A. M. Harmsze
, J. W. van Werkum
, et al.
·
European Heart Journal
·
159
Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population
1999
·
A AYNACIOGLU
, C SACHSE
, et al.
·
Clinical Pharmacology & Therapeutics
·
157
Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy*
1997
·
Atsuko Odani
, Yukiya Hashimoto
, et al.
·
Clinical Pharmacology & Therapeutics
·
155
Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population
2002
·
Samar Ismail Hamdy
, Masahiro Hiratsuka
, et al.
·
British Journal of Clinical Pharmacology
·
154
PDF
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
2001
·
Jiu‐Hui Wang
, Zhao‐Qian Liu
, et al.
·
Clinical Pharmacology & Therapeutics
·
150
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
2010
·
D. SIBBING
, D. GEBHARD
, et al.
·
Journal of Thrombosis and Haemostasis
·
146
Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe
2019
·
Jelena Petrović
, Vesna Pešić
, et al.
·
European Journal of Human Genetics
·
144
PDF
Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention
2012
·
Matthew J. Price
, Sarah S. Murray
, et al.
·
Journal of the American College of Cardiology
·
139
PDF
Show more works
View as search
Works count:
919
Citation count:
19,630
Year
Topic
Type